BIOPROCESS CONTAINERS MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Bioprocess Containers Market Size and Trends

Global bioprocess containers market is estimated to be valued at USD 3.67 Bn in 2024 and is expected to reach USD 9.52 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 14.6% from 2024 to 2031.

To learn more about this report, request sample copy

Global bioprocess containers market is witnessing growth due to increasing monoclonal antibody production. Rising adoption of personalized medicine and growing demand for genetically engineered products boosts the need for increased bioprocessing capacity. However, the market faces challenges such as lack of standardized regulatory framework. But continued technological advancements in production processes is expected to drive the bioprocess containers market.

Market Driver – Increasing Product Launch by Key Market Players

Increasing adoption of organic growth strategies such as product launches by key market players is expected to drive the global bioprocess containers market growth over the forecast period. For instance, in February 2021, Thermo Fisher Scientific, Inc., a medical device company, announced the launch of single-use, sterilized, closed-system bioprocess container (BPC) that is designed to offer a highly efficient alternative. CentriPAK BPC enables optimal protection of critical sterile liquids from cross-contamination typically associated with reusable containers.

The biopharmaceutical industry has been witnessing a significant transition from traditional stainless-steel bioreactors to single-use bioprocess containers in the recent years. Many manufacturers are actively switching to single-use technologies for fermentation as well as downstream and upstream applications as it provides numerous advantages over traditional systems. Single-use bioprocess containers have substantially reduced the costs associated with cleaning and validation of stainless-steel equipment. These eliminate the need for complex and expensive cleaning procedures between production batches. This allows for faster production turnarounds and greater manufacturing flexibility. New therapies and drugs can be quickly developed and brought to clinical trials. This has become a critical necessity as the demand for personalized medicines and complex biologics increases. Many biopharma companies involved in gene and cell therapies heavily rely on single-use technologies due to their processing sensitivities. Any residual contaminants left behind during cleaning can potentially compromise the efficacy and safety of these advanced therapies. The sterility and consistency assured by single-use systems are particularly valuable for products requiring high purity levels.